ENZ, – StockHotTips.com Stock in Focus for Tuesday
Stockhottips Newsletter
(Mailing list information, including instructions, is located at the end of this message.)
Enzo Biochem, Inc. (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.
ENZ has concentrated on the development of enabling technologies in the areas of gene regulation and gene modification. Many of ENZ ’s technologies are applicable to the biomedical and pharmaceutical research markets, and ENZ is further using these technologies as a platform for its entry into the clinical diagnostics market.
ENZ ’s work in gene analysis has led to development of a number of significant therapeutic candidates for the treatment of viral and immunological based disorders, several of which are in various phases of human clinical trials. In the course of its extensive research and development activities, ENZ has built a significant patent position consisting of numerous pioneer patents and applications that encompass its core technologies.
ENZ are performed by the company’s three wholly owned subsidiaries . . . Enzo Life Sciences , Enzo Therapeutics and Enzo Clinical Labs .
Enzo Life Sciences is a leading manufacturer of high quality reagents, kits and products supplied to scientific researchers in academia, clinical research and drug discovery. With direct sales operations in US, Switzerland, Germany, UK, France and Benelux, Enzo Life Sciences also supports its 8000 products through a global network of dedicated distributors.
Enzo Clinical Labs is much more than a highly respected clinical laboratory. Its lab is utilized extensively to demonstrate the benefits of gene-based products developed at Enzo Life Sciences . It also plays an important role in the development of and performance of tests used to support the on going trials of Enzo Therapeutics .
Enzo Therapeutics is a growing and expanding biotechnology company, currently conducting research that is on the forefront of several fields of medical science. Enzo Therapeutics is developing new products and therapies based on novel technology platforms for the treatment of a variety of diseases and disorders.
Enzo Therapeutics ` product pipeline reaches into a broad range of markets with therapeutic modalities for inflammatory bowel disease, uveitis, HIV infection, bone disorders , diabetes, and other immune mediated diseases.
Inflammatory Bowel Disease
Uveitis
ENZ ’s candidate drug based on Enzo`s immune regulation technology platform is a potential therapy for autoimmune uveitis.
ENZ ’s Enzo Therapeutics division commenced a clinical trial of Optiquel, the Company’s proprietary oral therapeutic for chronic non-infectious uveitis (a collective term for a variety of ophthalmic conditions that result in chronic inflammation of the eye involving the uvea, which lies between the outermost and innermost layers of the eye).
Enzo Therapeutics ‘ Optiquel has been awarded orphan drug status in the European Union and a similar designation may be applied for in the US. ENZ owns the exclusive rights to both US and international patents claiming the use of this compound for the treatment of uveitis. An investigator-initiated clinical trial of Optiquel™ in Germany demonstrated a therapeutic effect with no treatment-related side effects.
HIV
Bone Disorders
Osteoporosis
Osteoporosis, meaning "porous bones", is a condition of weakened and brittle bones that become more prone to fracture. The 10-billion dollar osteoporosis market is crowded with bone-preserving drugs such as bisphosphonates and selective estrogen receptor modulators, commonly referred to as SERMS. Bone-building drugs such as Enzo`s candidate compounds offer the potential for promising alternatives.
Periodontitis
One of the most challenging problems chronicled throughout the history of clinical dentistry is the loss of alveolar bone. Alveolar bone loss is characterized by a reduction in the height and volume of the maxillary and mandibular bones that underlie and support the teeth. The primary causes of alveolar bone loss are periodontitis and tooth loss, although osteoporosis may also contribute.
ENZ ’s candidate bone-building drugs may be such an approach.
Diabetes
ENZ ’s candidate drug compounds, that have been shown to lower blood glucose in animal model systems of diabetes, show considerable promise as a therapy for diabetes.
Enzo Biochem, Inc. (NYSE:ENZ) recently reported improved sequential results for the first fiscal quarter ended October 31, 2010:
) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Stockhottips.com